News

The submitted pre-IND package provides the US FDA with information on the company’s REV-002, as well as a clinical trial plan for a proposed US clinical trial. The

The final closing of the transaction is expected to take place on or before 07 July 2014. The acquisition is a significant milestone for GelStat and is expected

Recently, the US Adopted Names (USAN) Council has adopted necuparanib as the unique non-proprietary name for M402. Necuparanib, a heparan sulfate mimetic, is a novel oncology drug candidate

The patent is expected to be issued during 2014 and will have a 2029 expiry date. RHB-104 is a proprietary antibiotic combination oral capsule formulation for the treatment

The claims of this National Stage Application cover delivery technology based on Marina’s proprietary SMARTICLES amphoteric liposomes and directly support the clinical programs of the company’s licensees ProNAi

In the trial, AD04 showed clinical and biomarker effects consistent with disease modification in Alzheimer patients. Following treatment with AD04, effects consistent with disease modification were achieved for

After a careful and prolonged pre start-up process, this highly qualified group of liver centers has already evolved into a formal alliance – LALREAN. Although the Scientific Leaders

COPE enables self-funded employers to offer access to TreatmentMAP to their employees via a pre-packaged offering, which includes materials for employees, as well as working closely with patients’

European regulatory authorities have finalized their assessment of reported non-compliance with Good Manufacturing Practice (GMP) at Toansa site that had led to the suspension of the GMP certificate